
Reset all filters
01 2Alliance revenue - Lenvima
02 6Lenvima
03 4Lenvima
04 3Lenvima/Kisplyx
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 1,283
2019 Revenue in Millions : 947
Growth (%) : 35
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 580
2019 Revenue in Millions : 404
Growth (%) : 44
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 704
2020 Revenue in Millions : 580
Growth (%) : 21
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 1,445
2020 Revenue in Millions : 1,230
Growth (%) : 27
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 876
2021 Revenue in Millions : 704
Growth (%) : 24
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 1,848
2021 Revenue in Millions : 1,445
Growth (%) : 28
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 1,909
2022 Revenue in Millions : 1,848
Growth (%) : 16
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 960
2022 Revenue in Millions : 876
Growth (%) : 10
Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 1,010
2023 Revenue in Millions : 960
Growth (%) : 5
Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 2,119
2023 Revenue in Millions : 2,145
Growth (%) : -1